Table 1

Key features of the included studies

AuthorYearLocationSample sizeParticipant ageCancer stageTreatment stage
Ene2006Sweden12363.1No data providedPretreatment to Post-treatment
Pirl2008USA5062AdvancedPre and On-treatment
Sharpley2007Australia19569.2LocalisedPost-treatment
Bisson2002Wales8364.5MixedPretreatment
Dirkson2009USA5173.4MixedOn-treatment
Dale2009USA6767.9No data providedPretreatment (but all participants had received prior primary therapy)
Gabershagen2007Germany11564.1LocalisedPretreatment
Gabershagen2009Germany8462.8MixedPretreatment to post-treatment
Hervouet2005Canada86167.9MixedPost-treatment
Monga1999USA3666LocalisedPretreatment to On-treatment to Post-treatment
Monga2005USA4067.8LocalisedPretreatment to On-treatment to Post-treatment
Pirl2002USA4569.4Localised and MetastaticOn-treatment
Savard2005Canada32766localisedPost-treatment
Stone2000England6269MixedOn-treatment
Soloway2004USA10362No data providedPretreatment
Steineck2002Finland32664.5LocalisedPost-treatment
Symon2006USA5059.9LocalisedPretreatment to Post-treatment
Sharpley2007Australia18369.2LocalisedPost-treatment
Sharpley2009Australia15069.8LocalisedPost-treatment
van Tol-Geerdink2006Holland11870LocalisedPretreatment
Van den Berg2009Holland12964.9LocalisedOn-treatment (active surveillance)
Van den Berg2010Holland12964.6LocalisedOn-treatment (active surveillance)
Monga2001USA4067.6LocalisedPretreatment to Post-treatment
Korfage2006Holland29965.4MixedPretreatment Post-treatment
Bitsika2009Australia381No dataLocalisedPost-treatment
Nordin2001Sweden118No dataLocalised & AdvancedPretreatment
Burnet2007England32968.8LocalisedOn-treatment and post-treatment